Heat-inactivated Lactobacillus plantarum nF1 promotes intestinal health in Loperamide-induced constipation rats

PLoS One. 2021 Apr 19;16(4):e0250354. doi: 10.1371/journal.pone.0250354. eCollection 2021.

Abstract

Constipation is a common condition that affects individuals of all ages, and prolonged constipation needs to be prevented to avoid potential complications and reduce the additional stress on individuals with pre-medical conditions. This study aimed to evaluate the effects of heat-inactivated Lactobacillus plantarum (HLp-nF1) on loperamide-induced constipation in rats. Constipation-induced male rats were treated orally with low to high doses of HLp-nF1 and an anti-constipation medication Dulcolax for five weeks. Study has 8 groups, control group; loperamide-treated group; Dulcolax-treated group; treatment with 3.2 × 1010, 8 × 1010 and 1.6 × 1011, cells/mL HLp-nF1; Loperamide + Dulcolax treated group. HLp-nF1 treated rats showed improvements in fecal pellet number, weight, water content, intestinal transit length, and contractility compared to the constipation-induced rats. Also, an increase in the intestine mucosal layer thickness and the number of mucin-producing crypt epithelial cells were observed in HLp-nF1-treated groups. Further, the levels of inflammatory cytokines levels were significantly downregulated by treatment with HLp-nF1 and Dulcolax. Notably, the metagenomics sequencing analysis demonstrated a similar genus pattern to the pre-preparation group and control with HLp-nF1 treatment. In conclusion, the administration of >3.2 × 1010 cells/mL HLp-nF1 has a positive impact on the constipated rats overall health.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Actinobacteria / genetics
  • Actinobacteria / growth & development
  • Actinobacteria / isolation & purification
  • Animals
  • Bacteroidetes / genetics
  • Bacteroidetes / growth & development
  • Bacteroidetes / isolation & purification
  • Bisacodyl / pharmacology
  • Constipation / chemically induced
  • Constipation / microbiology
  • Constipation / therapy*
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism
  • Feces / microbiology
  • Firmicutes / genetics
  • Firmicutes / growth & development
  • Firmicutes / isolation & purification
  • Gastrointestinal Transit / drug effects*
  • Gastrointestinal Transit / physiology
  • Gene Expression / drug effects
  • Hot Temperature
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • Intestinal Mucosa / drug effects*
  • Intestinal Mucosa / microbiology
  • Lactobacillus plantarum / physiology*
  • Laxatives / pharmacology*
  • Loperamide / adverse effects
  • Male
  • Metagenome*
  • Microbial Viability
  • Proteobacteria / genetics
  • Proteobacteria / growth & development
  • Proteobacteria / isolation & purification
  • RNA, Ribosomal, 16S / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism
  • Verrucomicrobia / genetics
  • Verrucomicrobia / growth & development
  • Verrucomicrobia / isolation & purification

Substances

  • IL1B protein, rat
  • Il6 protein, rat
  • Interleukin-1beta
  • Interleukin-6
  • Laxatives
  • RNA, Ribosomal, 16S
  • Tumor Necrosis Factor-alpha
  • Bisacodyl
  • Loperamide
  • Cyclooxygenase 2
  • Ptgs2 protein, rat

Grants and funding

Biogenics Korea provided support for this study in the form of salary for IYK. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.